2015 Press Releases

Webcast ImageWebcast
AVEO Oncology at the Jefferies 2017 London Healthcare Conference (Replay)
11/15/17 at 4:00 p.m. GMT
AVEO Oncology at the Jefferies 2017 London Healthcare Conference
Wednesday, November 15, 2017 4:00 p.m. GMT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
AVEO Oncology at the Piper Jaffray 29th Annual Healthcare Conference (Live)
11/28/17 at 10:00 a.m. ET
AVEO Oncology at the Piper Jaffray 29th Annual Healthcare Conference
Tuesday, November 28, 2017 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/21/15AVEO and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib in Europe
EUSA to Submit Marketing Authorization Application for Tivozanib in Advanced RCC in Q1 2016 AVEO to Host Conference Call Today, December 21, 2015 at 9:00 AM ET CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--Dec. 21, 2015-- AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma ... 
Printer Friendly Version
11/09/15AVEO Oncology Reports Third Quarter 2015 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update. “We completed partnerships for two of AVEO’s lead programs in the third quarter in addition to making progress toward our proposed plans to submit a European Marketing Authorization Application (MAA) for tivozanib in renal cancer and initiate a pivotal study i... 
Printer Friendly Version
11/09/15AVEO Announces Chairman Tuan Ha-Ngoc Steps Down
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, after 13 years of service and leadership at AVEO, has stepped down as Chairman and a Director of the Company’s board of directors, effective November 6, 2015, to pursue interests outside the Company. Henri A. Termeer, Lead Outside Director of AVEO, has assumed Board leadership responsibilities. “Tuan has played a fundamental role in bu... 
Printer Friendly Version
08/17/15AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related Antibodies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 17, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody (the “Product”). Under the terms of the ag... 
Printer Friendly Version
08/10/15AVEO Oncology Reports Second Quarter 2015 Financial Results
Company to Host Midyear Update Conference Call Today, August 10 at 10:00 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 10, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015. “The second quarter was productive on multiple fronts for AVEO, including clinical updates, regulatory guidance and another partnership for tivozanib, in addition to completion of our corporate streamlini... 
Printer Friendly Version
08/05/15AVEO Oncology to Host Midyear Update Conference Call on August 10, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015, at 10:00 a.m. Eastern Time to provide an update on recent developments and corporate goals, as well as discuss financial results for the second quarter ended June 30, 2015. The call can be accessed by dialing 1-866-428-2694 (domestic) or 1-704-908-0403 (international) five minutes pr... 
Printer Friendly Version
08/05/15AVEO Oncology Announces Exclusive Licensing Agreement with Pharmstandard for Tivozanib in Russia, Ukraine and CIS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”), for the development, manufacturing and commercialization of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the ... 
Printer Friendly Version
06/30/15AVEO Oncology Announces Additional Biomarker Analyses from BATON-CRC Tivozanib Study to be Presented at the ESMO 17th World Congress on Gastrointestinal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 30, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the European Society for Medical Oncology (ESMO) 17th World Congress on Gastrointestinal Cancer, taking place July 1-4 in Barcelona, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth facto... 
Printer Friendly Version
06/11/15AVEO Announces FDA Update for Tivozanib in Colorectal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 11, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors. ... 
Printer Friendly Version
06/03/15AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 3, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC), it has received written confirmation of support from the Rapporteur and co-Rapporteur for the filing of such an application. The Rapporteur (from Portugal) and... 
Printer Friendly Version
05/29/15AVEO Oncology to Present at Jefferies 2015 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay of the webcast ... 
Printer Friendly Version
05/26/15AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts
Unveils New Corporate Logo CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 26, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective today. Consistent with the Company’s goal of streamlining operations to align with its needs going forward, the new facility consists of approximately 5,000 square feet of office space under flexible lease terms, with ... 
Printer Friendly Version
05/20/15AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 20, 2015-- AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meetin... 
Printer Friendly Version
05/07/15AVEO Oncology Reports First Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015. “We continue to execute on our strategy of leveraging biomarker insights and exploring partnership opportunities to advance our pipeline, while continuing to streamline AVEO’s operations to align with our needs,” said Michael Bailey, president and chief executive officer. “In parallel, we... 
Printer Friendly Version
04/22/15AVEO Names Keith S. Ehrlich as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 22, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and management, and will serve on the executive leadership team which governs corporate strategy. He will report to Michael Bailey, AVEO’s president and chief executive officer. ... 
Printer Friendly Version
04/20/15AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at 2015 Annual Meeting of the American Association of Cancer Research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 20, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly increased plasma GDF15 levels. The data were presented in a poster titled “Effective treatment of cancer associated cachexia by AV-38... 
Printer Friendly Version
03/06/15AVEO Oncology Reports Full Year 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014. “At the beginning of 2015, AVEO implemented several important changes designed to maximize the value of our portfolio of clinical stage products,” said Michael Bailey, president and chief executive officer. “Our approach to realizing this value is to leverage biomarker insights, including... 
Printer Friendly Version
03/06/15AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC
Results Presented at AACR Tumor Angiogenesis and Vascular Normalization Conference AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of... 
Printer Friendly Version
02/27/15AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker Analysis from Phase 2 Study of Tivozanib in Patients with Advanced Colorectal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.m. Eastern Time to discuss the presentation of final results and a predefined biomarker analysis of its BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer. The presentation, titl... 
Printer Friendly Version
01/12/15AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 12, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at aveooncology.com. A replay of the webca... 
Printer Friendly Version
01/09/15AVEO Names Michael N. Needle, M.D., As Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the Company’s partnered and proprietary pipeline programs. He will report to Michael Bailey, AVEO’s president and ch... 
Printer Friendly Version
01/08/15AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency
Company to Evaluate Potential for Submission of a Tivozanib MAA for the Treatment of RCC CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency’s centralized procedure. Confirmation of eligibility was giv... 
Printer Friendly Version
01/07/15AVEO Announces Executive Transition and Corporate Restructuring
Michael P. Bailey Named President and Chief Executive Officer; Tuan Ha-Ngoc Named Chairman of the Board Company to Eliminate Internal Research Function to Align Corporate Resources with the Company’s Future Strategic Plans CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 7, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that its Board of Directors has appointed Michael P. Bailey as the Company’s president and chief executive officer and has... 
Printer Friendly Version